Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
43.67
-1.61 (-3.56%)
At close: Oct 12, 2026, 4:00 PM EDT
43.85
+0.18 (0.40%)
After-hours: Oct 12, 2026, 7:30 PM EDT
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,480 employees as of June 30, 2026. The number of employees increased by 78 or 5.56% since the number was reported on December 31, 2025. That makes Ionis Pharmaceuticals the 12,188th largest employer in the world and 1,928th in the United States.
Employees
1,480
Change
78
Growth
5.56%
Revenue / Employee
$590,603
Profits / Employee
-$381,874
Market Cap
7.26B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 1,480 | 78 | 5.56% |
| Dec 31, 2025 | 1,402 | 333 | 31.15% |
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Iovance Biotherapeutics | 975 |
| Arrowhead Pharmaceuticals | 711 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
| Praxis Precision Medicines | 168 |
| Kodiak Sciences | 141 |
| Spyre Therapeutics | 125 |
IONS News
- 19 days ago - Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN) - Business Wire
- 20 days ago - Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study - Reuters
- 20 days ago - Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment - Business Wire
- 20 days ago - Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS - Business Wire
- 20 days ago - Ionis Pharmaceuticals price target lowered to $70 from $76 at JPMorgan - TheFly
- 21 days ago - Cathie Wood’s ARK Investment buys 100K shares of Ionis Pharmaceuticals today - TheFly
- 26 days ago - Ionis Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 27 days ago - Ionis Pharmaceuticals price target lowered to $80 from $89 at Guggenheim - TheFly